Preparation, characterization and in vitro bioactivity of N-terminally PEGylated staphylokinase dimers

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Process Biochemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.PROCBIO.2011.10.004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase.

  2011cited by this paper
• Synthesis of N-terminally linked protein and peptide dimers by native chemical ligation.

  2010cited by this paper
• A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b.

  2009cited by this paper
• PEGylation of Val-1(alpha) destabilizes the tetrameric structure of hemoglobin.

  2009cited by this paper
• The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.

  2008cited by this paper
• Influence of intramolecular cross-links on the molecular, structural and functional properties of PEGylated haemoglobin.

  2007cited by this paper
• Construction,over-expression and activity analysis of a novel variant of staphylokinase with reduced antigenicity

  2007cited by this paper
• Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin.

  2006cited by this paper
• PEGylation, successful approach to drug delivery.

  2005cited by this paper
• Effect of pegylation on pharmaceuticals

  2003cited by this paper
• Effect of Ethylene Glycol and Polyethylene Glycol on the Acid-Unfolded State of Trypsinogen

  2003cited by this paper
• N-Terminal Site-Specific Mono-PEGylation of Epidermal Growth Factor

  2003cited by this paper
• Chemistry for peptide and protein PEGylation.

  2002cited by this paper
• Mono-N-terminal poly(ethylene glycol)-protein conjugates.

  2002cited by this paper
• Pegylation: a novel process for modifying pharmacokinetics.

  2001cited by this paper
• Peptide and protein PEGylation: a review of problems and solutions.

  2001cited by this paper
• Polyethylene Glycol–Derivatized Cysteine-Substitution Variants of Recombinant Staphylokinase for Single-Bolus Treatment of Acute Myocardial Infarction

  2000cited by this paper
• Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors.

  1998cited by this paper
• Mapping of recombinant hemoglobin using immobilized trypsin cartridges.

  1997cited by this paper
• The fibrinolytic activity of staphylokinase mutants in the fibrin plate assay.

  1995cited by this paper
• A cross-linked monoclonal antibody fragment for improved tumor targeting.

  1995cited by this paper
• Overproduction of staphylokinase in Escherichia coli and its characterization.

  1985cited by this paper

• A new site-specific monoPEGylated β-lactoglobulin at the N-terminal: Effect of different molecular weights of mPEG on its conformation and antigenicity.

  2021cites this paper
• Protein modification by bis-alkylation

  2020cites this paper
• Purification and in vivo stability and half-life of recombinant lipid modified staphylokinase.

  2020cites this paper
• Conjugation of staphylokinase with the arabinogalactan-PEG conjugate: Study on the immunogenicity, in vitro bioactivity and pharmacokinetics.

  2019cites this paper
• Site specific PEGylation of β-lactoglobulin at glutamine residues and its influence on conformation and antigenicity.

  2019cites this paper
• Structural Biology and Protein Engineering of Thrombolytics

  2019cites this paper
• Structure-based antigenic epitope and PEGylation improve the efficacy of staphylokinase

  2017cites this paper
• Interferon dimers: IFN-PEG-IFN

  2017cites this paper
• N-Terminal Modification with Pseudo-Bifunctional PEG-Hexadecane Markedly Improves the Pharmacological Profile of Human Growth Hormone.

  2015cites this paper
• PEGylated recombinant human interferon-ω as a long-acting antiviral agent: structure, antiviral activity and pharmacokinetics.

  2014cites this paper
• Phenyl amide linker improves the pharmacokinetics and pharmacodynamics of N-terminally mono-PEGylated human growth hormone.

  2014cites this paper
• Reversible protection of Cys-93(β) by PEG alters the structural and functional properties of the PEGylated hemoglobin.

  2014cites this paper
• Heat treatment increases the bioactivity of C-terminally PEGylated staphylokinase

  2014cites this paper
• N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.

  2013cites this paper
• PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine.

  2013cites this paper
• Phenyl linker-induced dense PEG conformation improves the efficacy of C-terminally monoPEGylated staphylokinase.

  2013cites this paper
• Molecular Insight into the Steric Shielding Effect of PEG on the Conjugated Staphylokinase: Biochemical Characterization and Molecular Dynamics Simulation

  2013influential citation
• Propylbenzmethylation at Val-1(α) markedly increases the tetramer stability of the PEGylated hemoglobin: a comparison with propylation at Val-1(α).

  2012cites this paper